<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00745225</url>
  </required_header>
  <id_info>
    <org_study_id>A111-101</org_study_id>
    <nct_id>NCT00745225</nct_id>
  </id_info>
  <brief_title>Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients</brief_title>
  <acronym>PPAR</acronym>
  <official_title>Targeting Peroxisome Proliferator-Activated Receptor-Gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients? (PROOF Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study whether peroxisome proliferator-activated receptor-gamma activation in peritoneal&#xD;
      dialysis patients will reduce inflammation, atherosclerosis, calcification and improve&#xD;
      survival of peritoneal dialysis patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peritoneal dialysis patients are at increased risk of cardiovascular morbidity and mortality&#xD;
      and are related to the presence of accelerated atherosclerosis. Other than the traditional&#xD;
      cardiovascular risk factors, there is increasing evidence that inflammation is associated&#xD;
      with the development of atherosclerosis and cardiovascular events in both the general and&#xD;
      dialysis population. C-reactive protein is predictive of higher all-cause mortality and&#xD;
      cardiovascular mortality, independent of other cardiovascular risk factors and&#xD;
      atherosclerotic vascular disease. As a considerable proportion of peritoneal dialysis&#xD;
      patients showed elevated C-reactive protein, it raises an important question as to whether&#xD;
      lowering C-reactive protein will have any cardiovascular and survival benefit in these&#xD;
      patients. On the other hand, insulin resistance with associated hyperinsulinemia is&#xD;
      frequently observed in chronic renal failure and dialysis patients. Although the exact&#xD;
      mechanism of insulin resistance needs further evaluation, studies indicated that insulin&#xD;
      resistance is an important cardiovascular risk factor and outcome predictor in the general&#xD;
      and dialysis population. Moreover, recent evidence indicates an association between chronic&#xD;
      inflammation and insulin resistance although the exact interrelationship remains unclear. The&#xD;
      peroxisome proliferator-activated receptor-gamma (PPAR-g) is a member of the nuclear receptor&#xD;
      family of ligand-dependent transcription factors. PPAR-g is highly expressed in adipose&#xD;
      tissue and clinical study has confirmed efficacy of the specific ligands for PPAR-gamma,&#xD;
      namely thiazolidinediones (TZD), in improving insulin sensitivity. Recent experimental and&#xD;
      clinical studies demonstrated that TZD has anti-inflammatory and anti-atherosclerotic&#xD;
      properties other than insulin sensitizing effect in type 2 diabetics. We hypothesize that&#xD;
      modulation of the PPAR-g activity may be a novel therapeutic strategy for reducing&#xD;
      inflammation and improving insulin sensitivity and may retard the progression of&#xD;
      atherosclerosis and possibly reduce mortality of our peritoneal dialysis patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2006</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind randomized placebo-controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind randomized placebo-controlled trial, all parties are masked</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in carotid intima-media thickness</measure>
    <time_frame>over 48 weeks</time_frame>
    <description>Change in carotid intima-media thickness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in flow mediated dilatation (marker of endothelial function)</measure>
    <time_frame>over 48 weeks</time_frame>
    <description>change in flow mediated dilatation (marker of endothelial function)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in aortic pulse wave velocity</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>change in aortic pulse wave velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in augmentation index-heart rate adjusted</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>change in augmentation index-heart rate adjusted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in nitroglycerin-mediated dilatation</measure>
    <time_frame>over 48 weeks</time_frame>
    <description>change in nitroglycerin-mediated dilatation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in coronary artery calcium score</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>change in coronary artery calcium score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in heart valves calcium score</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>change in heart valves calcium score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in carotid artery calcium score</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>change in carotid artery calcium score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in abdominal visceral fat</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>change in abdominal visceral fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in subcutaneous fat</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>change in subcutaneous fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in blood pressure</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>change in blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in C-reactive protein</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>change in C-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in residual kidney function</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>change in residual kidney function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in HOMA index (among those not on insulin)</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>Change in insulin resistance index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in D/P creatinine ratio</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>Change in peritoneal solute transport parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in peritoneal ultrafiltration with 2.5% during PET</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>Change in peritoneal ultrafiltration volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in handgrip strength</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>change in handgrip strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac biomarkers</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>change in cardiac biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in insulin dose (among those on insulin)</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>change in insulin dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in endothelial progenitor cells</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>change in endothelial progenitor cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in central systolic blood pressure</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>change in central systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in central diastolic blood pressure</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>change in central diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in glycemic control (fasting glucose, and glycosylated hemoglobin)</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>change in glycemic control</description>
  </secondary_outcome>
  <other_outcome>
    <measure>overall survival</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>Hard outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>major adverse cardiovascular event-free survival</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>hard outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Fluid overload/heart failure event-free survival</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>hard outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>myocardial infarction event-free survival</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>hard outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>3 point major adverse cardiovascular event-free survival</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>Hard outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>4 point major adverse cardiovascular event-free survival</measure>
    <time_frame>over 96 weeks</time_frame>
    <description>Hard outcome</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Active intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peroxisome proliferator activator receptor gamma treatment, Pioglitazone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>pioglitazone 15mg daily for 12 weeks, then 30mg daily for 84 weeks</description>
    <arm_group_label>Active intervention arm</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo comparator</intervention_name>
    <description>1 capsule daily, 96 weeks.</description>
    <arm_group_label>placebo pill</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Both prevalent patients or patients newly started on continuous peritoneal dialysis,&#xD;
             with or without diabetes mellitus will be considered eligible for study entry.&#xD;
&#xD;
          -  For patients newly started on chronic peritoneal dialysis, they will be suitable for&#xD;
             recruitment into the study after one month on peritoneal dialysis.&#xD;
&#xD;
          -  Patients who provide informed consent for the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with underlying active malignancy&#xD;
&#xD;
          -  Patients with chronic liver disease or liver cirrhosis&#xD;
&#xD;
          -  Patients with active infections&#xD;
&#xD;
          -  Patients with other chronic active inflammatory disease such as systemic lupus&#xD;
             erythematosus, rheumatoid arthritis&#xD;
&#xD;
          -  Patients who refuse study participation&#xD;
&#xD;
          -  Patients with underlying congenital heart disease or rheumatic heart disease&#xD;
&#xD;
          -  Patients with poor general condition&#xD;
&#xD;
          -  Patients with plans for living related kidney transplant within 2 years&#xD;
&#xD;
          -  Female patients with pregnancy&#xD;
&#xD;
          -  Patients with history of recurrent hypoglycemia&#xD;
&#xD;
          -  Patients with Class III and IV congestive heart failure&#xD;
&#xD;
          -  Patients already receiving glitazones treatment at the screening visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela YM Wang, MD, PhD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hong Kong, Queen Mary Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Mary Hospital, Tung Wah Hospital</name>
      <address>
        <city>Hong Kong</city>
        <zip>0000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 1, 2008</study_first_submitted>
  <study_first_submitted_qc>September 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2008</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Angela Yee-Moon Wang</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>peritoneal dialysis, cardiovascular, PPAR-gamma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

